October 2023

Traitement par le bimekizumab chez des patients naïfs de DMARD biologiques atteints de rhumatisme psoriasique actif : résultats d'efficacité et de sécurité à 52 semaines de l'étude BE OPTIMAL de phase III, randomisée, contrôlée par placebo et à référence active

Ann Rheum Dis. 2023;82(11):1404–1414 doi: 10.1136/ard-2023-224431

Data from this phase 3 RCT demonstrated that the efficacy of bimekizumab observed at 16 weeks remained consistent through to 52 weeks in the treatment of bDMARD-naïve patients with PsA. Patients who started the trial on placebo and switched to bimekizumab at week 16 showed similar improvements to those patients who were randomised to receive bimekizumab at the start of the trail. No new safety signals were identified.

Keywords:

July 2023

Amélioration des résultats rapportés par les patients et de la productivité au travail après 3 ans de traitement par l'ustekinumab ou par un inhibiteur du facteur de nécrose tumorale chez les patients atteints de rhumatisme psoriasique : Résultats de l'étude PsABio en situation réelle

Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y

Results from the 3-year PsABio study demonstrated that, generally, ustekinumab and TNFi treatment led to an improvement in PROs. In coming to this conclusion, researchers aimed to evaluate the real-world effect of ustekinumab or a TNFi on PRO and their association with effectiveness endpoints in PsA patients over 3 years.

Keywords:

March 2023

Gender-specific Differences in Patients with Psoriatic Arthritis Receiving Ustekinumab or Tumour Necrosis Factor Inhibitor: Real-world Data

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead089

These real-world data from PsABio on gender differences suggest that, at the start of biologic treatment, females have a worse clinical picture of PsA than males. In coming to these conclusions and others, this study sought to investigate effects of gender on disease characteristics and treatment impact in patients with PsA.

Keywords:

January 2023

Innocuité et efficacité du bimekizumab chez les patients atteints de rhumatisme psoriasique actif : Résultats à trois ans d'un essai contrôlé randomisé de phase IIb et de son étude de prolongation ouverte

Arthritis Rheumatol. 2022 doi: 10.1002/art.42280

This study highlighted that the safety of bimekizumab in patients with PsA over 3 years of treatment was consistent with the previous 48-week results, as well as other recently published studies of IL-17 inhibitors in PsA patients.

Keywords:

Bimekizumab chez des patients atteints de rhumatisme psoriasique actif et ayant déjà présenté une réponse inadéquate ou une intolérance aux inhibiteurs du facteur de nécrose tumorale : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo (BE COMPLETE))

Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0

This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.

Keywords:

Bimekizumab chez des patients atteints de rhumatisme psoriasique, naïfs de traitement biologique : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo (BE OPTIMAL)

Lancet. 2023 doi: 10.1016/S0140-6736(22)02302-9

This study showed that bimekizumab treatment resulted in clinically meaningful and consistent improvements across multiple measures in bDMARD-naïve patients with active PsA. It aimed to assess the efficacy and safety of bimekizumab in patients with active PsA who were naive to bDMARDs.

Keywords: